Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity. This is further to the company?s previous intimation of 27 March 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva. The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
298.6 INR | -2.72% | -3.94% | +19.63% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
298.6 INR | -2.72% | -3.94% | 4.39B | ||
3.38 RON | +1.20% | +3.68% | 509M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.63% | 4.39B | |
+2.93% | 108B | |
-1.95% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution